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Skeletal developmenty plays essential roles in endochondral ossiﬁcation by regulating osteoblast
proliferation and differentiation, chondrocyte proliferation, hypertrophy, and apoptosis. FGF signaling is
controlled by the complementary action of both positive and negative regulators of the signal transduction
pathway. The Spry proteins are crucial regulators of receptor tyrosine kinase-mediated MAPK signaling
activity. Sprys are expressed in close proximity to FGF signaling centers and regulate FGFR-ERK-mediated
organogenesis. During endochondral ossiﬁcation, Spry genes are expressed in prehypertrophic and
hypertrophic chondrocytes. Using a conditional transgenic approach in chondrocytes in vivo, the forced
expression of Spry1 resulted in neonatal lethality with accompanying skeletal abnormalities resembling
thanatophoric dysplasia II, including increased apoptosis and decreased chondrocyte proliferation in the
presumptive reserve and proliferating zones. In vitro chondrocyte cultures recapitulated the inhibitory effect
of Spry1 on chondrocyte proliferation. In addition, overexpression of Spry1 resulted in sustained ERK
activation and increased expression of p21 and STAT1. Immunoprecipitation experiments revealed that Spry1
expression in chondrocyte cultures resulted in decreased FGFR2 ubiquitination and increased FGFR2 stability.
These results suggest that constitutive expression of Spry1 in chondrocytes results in attenuated FGFR2
degradation, sustained ERK activation, and up-regulation of p21Cip and STAT1 causing dysregulated
chondrocyte proliferation and terminal differentiation.
© 2008 Elsevier Inc. All rights reserved.IntroductionDuring endochondral bone development, a cartilage template forms
whenmesenchymal cells condense and differentiate into chondrocytes.
These chondrocytes then undergo a program of proliferation, hyper-
trophy, calciﬁcation, and cell death. Several families of signaling
molecules have been identiﬁed that act at multiple points in skeletal
development. FGFR3 has been extensively investigated during endo-
chondral ossiﬁcation. Mice with a loss-of-function mutation in Fgfr3
have abnormal long bone growth (Colvin et al., 1996; Deng et al., 1996),
whereas mice with constitutively activating mutations of Fgfr3 exhibit
dwarﬁsm (Chen et al., 1999; Chen et al., 2001; Iwata et al., 2001). In
humans, Fgfr3 mutations result in several skeletal disorders, including
achondroplasia (Rousseau et al., 1994), hypochondroplasia (Bellus et al.,
1995), and thanatophoric dysplasia type I and type II (TDII) (Rousseau et
al., 1996; Rousseau et al., 1995; Tavormina et al., 1995). Although the
STAT1-p21Cip pathway is implicated in achondroplasia mediated by
Fgfr3 mutations and in Fgf2 transgenic mice (Sahni et al., 2001; Su et
al., 1997), the ERK pathway is also a major pathway transmitting FGFR-
mediated signals for chondrocyte proliferation, differentiation, andl rights reserved.apoptosis (Ornitz and Marie, 2002). Transgenic mice expressing
constitutively active MEK1 in chondrocytes exhibit the inhibition of
hypertrophic differentiation of chondrocytes and a delay of endochon-
dral ossiﬁcationwithout affecting chondrocyte proliferation (Murakami
et al., 2004). This effect is independent of the Stat1 pathway, however
constitutively active MEK1 rescues the Fgfr3−/− phenotype. Targeted
overexpression of CNP in chondrocytes counteracts dwarﬁsm in a
mouse model of achondroplasia by reversing the decrease in extra-
cellular matrix synthesis in the growth plate by inhibition of FGFR-
mediated ERK signaling (Yasoda et al., 2004). Thus, FGF signaling plays
crucial roles in limb speciﬁcation and endochondral bone formation
through the STAT1-p21Cip and ERK pathways.
Spry family members are feedback inhibitors of FGFR-mediated
activation of the ERK pathway, as well as other receptor tyrosine
kinases (RTKs) (Mason et al., 2006; Tsang and Dawid, 2004). In Dro-
sophila, null mutations in Spry cause hyperactivation of the FGF
pathway and ectopic secondary tracheal branching (Hacohen et al.,
1998). Overexpression of Spry during primary branch outgrowth
causes the opposite effect, inhibiting the FGF inductive pathway and
blocking secondary branching. Mammalian Spry proteins colocalize
with FGFs, most notably Fgf8 and Fgf3, during early vertebrate
embryogenesis in regions of the midbrain–hindbrain boundary, limb
buds, and craniofacial primordia (Minowada et al., 1999). FGF
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as a feedback inhibitor of the pathway that induces its expression
(Mason et al., 2006; Minowada et al., 1999). Conditional deletion of
Spry1with HoxB7-Cre results in mouse embryos with supernumerary
ureteric buds, resulting in the development of multiple ureters and
multiple kidneys (Basson et al., 2005). This aberrant development is
due to increased sensitivity of the Wolfﬁan duct to GDNF/RETS
signaling. In addition, targeted deletion of Spry2 causes defects of the
inner ear (Shim et al., 2005) and diastema development (Klein et al.,
2006), with no other discernable phenotype (Klein et al., 2006; Shim
et al., 2005). Targeted deletion of Spry4 also causes defects in tooth
development, and syndactyly (Taniguchi et al., 2007). Retroviral
overexpression of mouse Spry2 in developing wing buds of chick
embryos retards chondrocyte differentiation and limb bud formation
(Minowada et al., 1999). Mice with both Spry2 and Spry4 null mutant
alleles deleted show multiple craniofacial and skeletal defects,
although the mechanisms for these defects have not been addressed
(Taniguchi et al., 2007). Despite recent advances in understanding the
roles of Spry proteins on the regulation of FGF receptor signaling
during embryogenesis, little is known about Spry's regulation of
endochondral ossiﬁcation.
Fgfr3 is expressed in the growth plate in an increasing gradient from
reserve to proliferating chondrocytes, and it is weakly expressed in
hypertrophic chondrocytes (Peters et al., 1993); whereas Fgfr2 expres-
sion is apparent in skeletogenic mesenchymal condensations at early
stages of development, and is localized to the perichondrium and
nascent epiphyseal plate at late stages of development. Fgfr1 is
expressed in the perichondrium and hypertrophic chondrocytes
(Ornitz, 2001; Ornitz and Marie, 2002). The close association of Spry
expression with FGF signaling centers prompted us to examine the
expression of Spry family members in the developing long bones of late
gestation mouse embryos. Our data indicate that Spry1, Spry2, and
Spry4 are expressed in prehypertrophic and hypertrophic chondrocytes.
Given the potential for functional redundancy between Spry family
members, and possible compensatory mechanisms that may function
due to targeted deletion of a single family member, we chose a
transgenic mouse approach to gain insight into Spry function in
growth plate development. We generated conditional transgenic mice
in which mSpry1 was overexpressed in Col2α1-expressing chondro-
cytes, and analyzed the morphological changes of long bones and the
possible mechanisms that may be involved. Results reported here
indicate that Spry1 dysregulates the duration of FGFR-mediated ERK
activation in chondrocytes through attenuating FGFR ubiquitinylation.
Thus, overexpression mSpry1 in chondrocytes results in a thanato-
phoric dysplasia type II-like phenotype similar to that of constitutively
active Fgfr3 mutants and FGF2 transgenic mice.Materials and methods
Histology, immunohistochemistry, immunoﬂuorescence, and in situ hybridization
For histological analysis, embryos were ﬁxed in 4% paraformaldehyde, embryo
limbs were embedded in OCT, and serial 7 μm frozen sections were prepared using
standard procedures. For immunohistochemistry, antibodies to phospho-MEK1/2 (Cell
Signaling), Spry1, Spry2, Spry4, p21Cip (Santa Cruz), and STAT1 (Cell Signaling) were
used. For in situ hybridization, plasmids were linearized with the appropriate
restriction enzymes and digoxygenin-labeled riboprobes were generated using a
digoxygenin RNA labeling kit (Roche) according to the manufacturer's protocol. Probes
for aggrecan (Agc), Indian Hedgehog (Ihh), collagen10α1 (Col10α1), collagen 2α1
(Col2α1), PTHrP receptor (Ppr), and osteocalcin (OC), were provided by Volkhard
Lindner (Maine Medical Center Research Institute). The full length Spry1/pCS2+
construct was linearized with EcoRI, and the RNA probe was generated using T7
promoter. For Spry2 and Spry4, cDNA was generated by PCR using full length Spry2/
pCS2+ and Spry4/pCS2+ respectively, and cloned into TOPO vector (Invitrogen). For
p21Cip, MMP-13, and MMP-9 cDNA was generated by RT-PCR, and cloned into TOPO
vector (Invitrogen). Antisense/TOPO constructs were linearized by EcoRV, and RNA
probes were generated using T7 promoter. Primers for PCR or RT-PCR were: 5′-
AGGCCAGAGCTCAGAGTGGCAACGG-3′ (forward) and 5′-CTCCCATCGCTGACCATCGCG-
TACAAC-3′ (reverse) for Spry2, 5′-ATGGAGCCCCCGGTTCCACAG-3′ (forward) and 5′-AGAAGTGCTTGTCTAGCTCTG-3′ (reverse) for Spry4, 5′-GCACCATGTCCAATCCTGGTG-3′
(forward) and 5′-TCAGGGTTTTCTCTTGAGAAG-3′ (reverse) for p21Cip, 5′-GGCACCATG-
CATTCAGCTATCCTG-3′ (forward) and 5′-CACCACAATATGGAATTTGTTGGCATGAC-3′
(reverse) for MMP-13, 5′-CTGCTCCTGGCTCTCCTGGCTTTCGGCTG-3′ (forward) and 5′-
CTCGTCGTCGTCGAAATGGGCATCTC-3′ (reverse) for MMP-9. The sections were pre-
treated with proteinase K and hybridized with the probes according to standard
procedures. Sense probes were used as controls. The color was developed with BM
purple (Roche), and counterstained with nuclear fast red.
Cell culture and differentiation
293Tcells, as well as 293T cells stably expressing Cre recombinase (Cre8 cells), were
grown in DMEM 10% fetal bovine serum (FBS) at 37 °C in a humidiﬁed atmosphere of 5%
CO2. The CAGGFP-Spry1 plasmid was transfected into 293Tor Cre8 cells using Genejuice
(Novagen) transfection reagent according to the manufacturer's instructions. The
prechondrocytic cell line, ATDC5 was maintained in F12/DMEM (1:1), 5% FBS
maintenance medium at 37 °C in a humidiﬁed atmosphere of 5% CO2, and
differentiation was induced by addition of 10 μg/ml insulin (Sigma) to the maintenance
medium. Primary chondrocytes were isolated by collagenase digestion of long bone
growth plates of 5–7 day-old wild-type or CAGGFP-Spry1; CAGGCre-ERTM (Hayashi and
McMahon, 2002), bitransgenic mice. The growth plates were carefully dissected free
from connective tissue in PBS, and the cartilage was minced into 1 mm3 fragments. The
cartilage fragments were placed into 10 ml 0.05% trypsin solution in serum free DMEM
medium, and incubated for 25 min at room temperature with moderate agitation. The
cartilage fragments were allowed to sediment and the trypsin solution was removed
and replaced with 10 ml of 0.3% collagenase in serum free DMEM, and incubated for
30 min at room temperature, followed by replacement with 10 ml of 0.06% collagenase
in DMEM medium containing 10% FBS. The fragments and solution were transferred to
10 cm Petri dishes and incubated overnight in an incubator at 37 °C in 5% CO2. The cell
suspension was transferred to a 50 ml tube and vortexed brieﬂy; the cells were then
ﬁltered through a 40 μm nylon mesh (BD, Falcon). The resulting cell suspension was
centrifuged at 1200 rpm for 5 min, and the cells were resuspended in 10 ml
maintenance medium and seeded onto a 10 cm dish. Primary chondrocytes fromwild-
type mice were induced to differentiate by the addition of 10 μg/ml insulin and were
harvested at various intervals for up to 18 days.
For growth assays, primary chondrocytes were seeded in triplicate into 12-well
plates at a density of 5×104 cells/ml (1 ml/well) in the presence 1 μM tamoxifen
(Sigma). Triplicate wells were harvested daily by trypsinization, and counted using a
Coulter counter. Student's t-test was used for statistical analysis. For immunoblotting,
the cells were lysed in HNTG buffer (25 mM HEPES pH 7.4, 150 mM NaCl, 10% glycerol,
1% Triton X-100, 1 mM EGTA), containing complete protease inhibitor cocktail (Roche)
and phosphatase inhibitors. Equal amounts of cellular protein were subjected to SDS-
PAGE on 10% acrylamide gels, and were electrophoretically transferred to nitrocellulose
membranes as described (Neilson and Friesel, 1996). Membranes were blocked with 5%
nonfat dry milk in TBS, probed with antibodies to Spry1, Spry2, Spry4 (Santa Cruz),
phospho-ERK1/2 (Sigma), p42/44ERK1/2 (Cell Signal), p21Cip (Upstate), and the bound
antibodies were visualized with horseradish peroxidase conjugated secondary
antibodies (BioRad) and enhanced chemiluminescence (ECL, Amersham Biosciences).
For immunoprecipitation, the cell lysates were incubated with FGFR2 rabbit antibody
(Santa Cruz), precipitated by protein A/G beads (Santa Cruz), and eluted in SDS sample
buffer, and subjected to immunoblotting with a ubiquitin antibody (Sigma).
Spry1 transgenic mouse model
The CAGCAT-Z vector (Sakai and Miyazaki, 1997) containing a chicken β-actin gene
(CAG) promoter-loxP-chloramphenicol acetyltransferase (CAT) gene-loxP-LacZ was
modiﬁed by replacing the CAT gene with the GFP open reading frame, and by replacing
LacZ with a myc/his-tagged mouse Spry1 open reading frame generated by PCR using
gene speciﬁc primers. The CAGGFP-Spry1 construct constitutively expresses GFP, and
upon Cre-mediated recombination, Spry1 expression is induced, with concomitant loss
of GFP marker expression. Transgene activation by Cre recombinase was validated in
Cre8 cells in vitro by immunoblotting using anti-myc antibodies (Upstate Biotech). The
puriﬁed, linearized construct was injected into the pronucleus of FVB oocytes by
standard procedures (Maine Medical Center Research Institute Transgenic Mouse
Facility).
The resulting mice were screened by PCR of genomic DNA for GFP expression, and
founder lines validated by genotyping using GFP-speciﬁc primers, 5′-CTCGAGCCAC-
CATGAGTAAAGGAGAAGAAC-3′ (forward) and 5′-CTTCACTATTTGTAGAGTTCATCCATGC-
3′ (reverse), which amplify a 733 bp fragment. CAGGFP-Spry1 founder lines were
identiﬁed and crossed to Col2α1-Cre transgenic mice (Sakai et al., 2001) (Jackson
Laboratory, ME).
The presence of Cre recombinase was identiﬁed by PCR using primers; 5′-
GCATTACCGGTCGATGCAACGAGTG-3′ (forward) and 5′-GAACGCTAGAGCCTGTTTTG-
CACGTT-3′ (reverse), which amplify a 370 bp fragment.
Recombinationwas conﬁrmed by immunoblot analysis of tail lysates by using an anti-
myc antibody. For some experiments, CAGGFP-Spry1 mice were crossed with CAGGCre-
ERTMmice (A. McMahon, Harvard). All mice were housed in a pathogen-free environment
under light, temperature, and humidity-controlled conditions. For timed pregnancies, the
plug date was deﬁned as E0.5. All experimental protocols were reviewed and approved by
the Maine Medical Center Institutional Animal Care and Use Committee.
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Skeletal preparations were performed as described (Ito et al., 2003). Brieﬂy, timed
pregnant females or newborn mice were euthanized by asphyxiation in CO2. Embryos
and neonates were skinned, eviscerated, and ﬁxed in 95% ethanol. The skeletons were
stained with Alcian blue, cleared in 1% KOH, and counterstained with alizarin red.
BrdU and TUNEL labeling
For BrdU incorporation, pregnant females were injected intraperitoneally with
1 ml/100 g body weight of BrdU (Roche) 2 h before embryo harvest. For some
experiments, pregnant females were injected with BrdU 36 h before collecting the
embryos. Immunohistochemical detection of BrdU was performed using a BrdU
detection kit (Roche) according to the manufacturer's instructions. The sections were
counterstained with methyl green. BrdU-positive chondrocytes in the reserve and
proliferating zones were quantiﬁed on a minimum of ﬁve sections per embryo using
Scion Image software, and expressed as a percentage of total chondrocytes. Statistical
analysis was performed using the Student's t-test. For TUNEL labeling, the ﬂuorescent
in situ Cell Death Detection kit (Roche) was used according to the manufacturer's
instructions, and the number of apoptotic cells per section was quantiﬁed.
RT-PCR analysis
Total RNA was extracted from ATDC5 cells or cultured primary chondrocytes using
Tri-Reagent (Sigma). The RNAwas treatedwith a DNA-free kit (Ambion) according to the
manufacturer's instructions. cDNAwas synthesized using 1 μg of total RNA and random
hexamers using the Cloned AMV First-strand synthesis kit (Invitrogen). The ﬁrst strand
cDNA product was subjected to PCR using PCR Supermix (Invitrogen). The primer
sequences for PCR were: 5′-GGGCCTATTAGGACGGTCTC-3′ (forward) and 5′-CACAGG-
TATCTGGAGCAGCA-3′ (reverse) for Spry1; 5′-GGTCTCGGAGCAGTACAAGG-3′ (forward)
and 5′-GTAGGCATGCAGACCCAAAT-3′(reverse) for Spry2; 5′-AGGCCAGAGCTCA-
GAGTGGCAACGG-3′ (forward) and 5′- CTCCCATCGCTGACCATCGCGTACAAC-3′ (reverse)
for Spry4; 5′-CATGACCCAGCGCTGCAAGG-3′ (forward) and 5′-CCTGGAAAGCTCT-
CAGCCGG-3′(reverse)for Ihh; 5′-GTCACTGTACTCAAGACTGCAG-3′ (forward) and 5′-
GAAACATTGGCCAGAACAGGAC-3′ (reverse) for FGFR3; 5′-TGCGACTTCAACAGCAACTC-3′
(forward) and 5′-GATGGAAATTGTGAGGGAGA-3′(reverse) for GADPH.
Results
The expression of Spry family members in developing long bones is
limited to prehypertrophic and hypertrophic zones
To begin to understand the biological function of Spry genes in
endochondral bone formation, we evaluated endogenous Spry geneFig. 1. The expression of Spry family members was detected in prehypertrophic and hypertro
cryosections. Spry expression overlapswith Ihh. (B) Immunohistochemistry for Spry1, Spry2, and S
to differentiate in the presence of insulin. (B) The expression of Spry1, 2, 4, FGFR3, and Ihh in ATDC
induction of differentiation (Con, no RT control). (C) Immunoblot detection of Spry1 and Spry2 pexpression and protein localization in limb cryosections fromE12.5, E14.5,
and E17.5 embryos. By in situ hybridization, Spry1 and Spry2 were not
detectable in E12.5 limb chondrocytes (data not shown), but were
detected in E14.5 and E17.5 in the prehypertrophic and hypertrophic
chondrocytes of the long bones (Fig. 1A), as well as in the vertebral
column, ribs, scapula, and occipital bone (data not shown). Spry4 showed
a similar expression pattern (data not shown). Immunohistochemistry
with Spry speciﬁc antibodies gave similar results for Spry1; however,
Spry2 was also detected by immunohistochemistry in the proliferating
zone (Fig. 1B). The reasons for these differences are unknown but may
indicate differences in sensitivity of our in situ hybridization probes and
the Spry2 antibodies or potential cross-reactivity of the Spry2 antibodies.
To determine whether the expression of Spry family members is
regulated in a temporal manner during chondrocyte differentiation,
we employed an in vitro assay using the prechondrocytic ATDC5 cell
line and primary mouse chondrocytes induced to differentiate in
response to insulin over 18 days. The RT-PCR results indicate that the
expression of Spry1, Spry2, and Spry4 were increased in a temporal
manner during differentiation of ATDC5 cells, beginning as early as
2 days after the addition of insulin and peaking around day 12 (Fig.1C).
This increase paralleled that of the well known chondrocyte
differentiation marker Ihh (Fig. 1C). Immunoblotting revealed that
Spry1 and Spry2 protein levelswere increased in a temporalmanner in
ATDC5 cells. While Spry1 mRNA levels steadily increased during
differentiation, Spry1 protein levels increased during the ﬁrst 6 days of
differentiation and then declined. The discrepancy betweenmRNA and
protein levels at later stages of differentiationmay reﬂect differences in
Spry2 protein stability or degradation at speciﬁc stages of differentia-
tion. Spry1 and Spry2 protein levels also increased during insulin-
induced differentiation of primary mouse chondrocytes (Fig. 1D).
These results suggest that an increase in the expression of Spry family
membersmay play a role in chondrocyte hypertrophy andmaturation.
Conditional expression of Spry1 in chondrocytes
To address the role of Spry1 in chondrocyte development, we
established mSpry1-inducible transgenic mouse lines, in which a
myc/his-tagged mSpry1 open reading frame was cloned into thephic chondrocytes. (A) In situ hybridization for Spry1, Spry2, and Ihh on E17.5 humerus
pry4 cryosections of E17.5 humeri. (C, D) ATDC-5 cells or primary chondrocyteswere induced
-5 was determined by RT-PCR on RNA samples collected on days 0, 2, 6,12, and 18 days after
rotein during differentiation ADTC-5 cells (ADTC-5) and primary chondrocytes (PC).
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enhancer and β-actin promoter. This vector was designated CAGGFP-
Spry1. The open reading frame of GFP is placed downstream of the
promoter and is ﬂanked by two loxP sites, followed by transcrip-
tional stop sequences to prevent Spry1 transgene expression until
Cre-mediated excision of the Floxed GFP sequences (Fig. 2). Mating
with Col2α1-Cre (Col2-Cre) transgenic mice (Sakai et al., 2001)
resulted in forced mSpry1 expression in the Col2α1-expressing
chondrocytes. The efﬁcacy of this approach was demonstrated by
transient transfection of the CAGGFP-Spry1 plasmid into 293T cells
or into Cre recombinase-expressing Cre8 cells. Immunoﬂuorescence
microscopy and immunoblotting revealed strong GFP expression
without Cre recombinase (Figs. 2B and C); whereas in Cre8 cells,
Spry1 yc/his was strongly expressed with concomitant loss of GFP
expression (Figs. 2B and C). To test Cre-mediated recombination in
vivo, CAGGFP-Spry1 mice were crossed with Col2α1-Cre mice.
Bitransgenic embryos were designated Spry1;Col2-Cre and demon-
strated Spry1 myc/his and GFP expression by immunoblotting
whereas embryos carrying only the GFP transgene did not express
detectable Spry1 myc/his, as determined by immunoblotting (Fig.
2D). Attempts to reveal Spry1 transgene protein expression by
immunohistochemistry of embryonic long bone sections were
unsuccessful, presumably because the level of Spry1 transgenic
protein was below the limit of detection of the myc antibody. Three
founder lines were identiﬁed that produced similar skeletal
phenotypes, and one was chosen for further study.Fig. 2. Strategy for the tissue-speciﬁc expression of Spry1 in transgenic mice. (A) Schemat
expressing chondrocytes. (B) In vitro recombination assay. Immunoﬂuorescence and phase-
transfected with a Cre-expressing plasmid (Cre-8 cells). (C) Immunoblot analysis of lysate
Without Cre, GFP protein is detected, whereas Spry1 protein is not. When Cre recombinase i
mice were crossed with Col2a1-Cre mice, protein was extracted from the tails of E16.5 embry
anti-GFP antibodies (upper panel) (⁎non-speciﬁc band). Genomic DNA was extracted from t
(lower panel). Only those samples that were PCR-positive for GFP and Cre expressed Spry1Spry1; Col2-Cre transgenic mice exhibit chondrodysplasia
During embryogenesis, we did not detect phenotypic or morpho-
logical differences between Spry1;Col2-Cre embryos and wild-type
embryos before E12.5. However, by E14.5, Spry1;Col2-Cre embryos
began to exhibit a dwarﬁng phenotype demonstrated by a shortened
overall body length (data not shown). By E16.5, Spry1;Col2-Cre
embryos had short limbs, shortened snouts, tails, and domed skulls
consistent with a dwarﬁng phenotype (Figs. 3A, B). The severity of the
skeletal abnormalities in Spry1;Col2-Cre mice resulted in neonatal
lethality within a few hours after birth, most likely due to respiratory
difﬁculties. Alcian blue and alizarin red staining of skeletal prepara-
tions of newborn Spry1;Col2-Cre mice and their control littermates
revealed that all skeletal elements derived by endochondral bone
formation were reduced in size and often malformed in the Spry1;
Col2-Cre mice (Figs. 3C–F, H, and I). The bones at the base of the skull,
such as the basioccipital bone and basisphenoid bone that are formed
by endochondral ossiﬁcation were remarkable smaller in the Spry1;
Col2-Cre mice (Figs. 3H, I). However, the size of calvarial bones were
minimally affected (Fig. 3D). In particular, the size of the frontal bone
was comparable in control and Spry1;Col2-Cre mice (Fig. 3D). The
mandibular bones of Spry1;Col2-Cre mice showed normal ossiﬁca-
tion, but were shorter and wider than that of their control littermates
(Fig. 3G). This imbalance between normal intramembranous and
aberrant endochondral ossiﬁcation could account for the domed skull
and short snout of Spry1;Col2-Cre mice. The ossiﬁcation of theic representation for the tissue-speciﬁc, Cre-inducible expression of Spry1 in Col2a1-
contrast images of 293T cells transfected with CAGGFP-Spry1 alone or 293T cells stably
s from cells transfected with CAGGFP-Spry1 alone or together with Cre recombinase.
s present, GFP expression is lost and Spry1 protein is now detected. (D) CAG-GFP-Spry1
os and subjected to immunoblot analysis using anti-Myc antibodies and reprobed with
he yolk sacs and subjected to PCR screening for the presence of GFP and Cre sequences
protein (D, lane 1).
Fig. 3. Spry1;Col2-Cre embryos exhibit skeletal dwarﬁsm. (A, B) At E16.5, Spry1;Col2-Cre mice showed short limbs, shortened tail, domed skull, and short snouts. Original
magniﬁcations 1× (A), and 2.5× (B). (C–I) Skeletal preparations stained by Alcian blue and alizarin red. (C) Lateral view of upper body, showing ossiﬁcation abnormalities in skull,
vertebrae, and ribs. (D) Dorsal view of cranium (⁎area of abnormal ossiﬁcation). (E) Overall chondrogenesis of the forelimbs was signiﬁcant reduced in Spry1;Col2-Cremice. (F) Dorsal
view of vertebrae and ribs. Ribs were deformed and smaller, and ossiﬁcation of the vertebrae was frequently absent in Spry1;Col2-Cre mice. However, the mandible (G) was shorter
and wider due to the failure of Meckel's cartilage to fully elongate. (H, J) The size and ossiﬁcation of bones of the basioccipital bone (H) and basisphenoid bone (I) in Spry1;Col2-Cre
mice were signiﬁcantly reduced relative to control mice.
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The rib cage and the thoracic cavity were smaller, and the ribs were
thin and irregular (Fig. 3F), which most likely contributed to early
postnatal death due to respiratory impairment.
Overexpression of Spry1 in chondrocytes inhibits bone formation by
inhibiting chondrocyte terminal differentiation and removal
Von Kossa staining of sections of E16.5 humeri from Spry1;Col2-
Cre transgenic mice and their Cre-negative littermates reveals that
there is some deposition of a mineralized matrix in the long bones of
Spry1;Col2-Cre embryos, however there is a failure in the formation of
trabecular bone (Figs. 4A and B). Instead of giving way to the
formation of ossiﬁcation centers, hypertrophic chondrocytes persisted
and accumulated a sparse mineralized matrix. In addition, in situ
hybridization for the osteogenic marker gene, osteocalcin, showed
that overexpression of Spry1 in chondrocytes resulted in a signiﬁcant
reduction in osteocalcin expression that correlated with inhibition of
the formation of the primary ossiﬁcation centers (Fig. 4C). Histological
examination showed that the normal pattern of chondrocyte
differentiation in Spry1 transgenic mice was disrupted (Figs. 4D, E).
Cryosections of limbs were stained with hematoxylin eosin and Alcian
blue to examine the growth plate morphology and the distribution ofsulphated glycosaminoglycans in the matrix. In control mice,
chondrocytes of the long bone growth plate were organized into
reserve, proliferating, and hypertrophic zones; however, the Spry1;
Col2-Cre mice had disorganized growth plates that lacked the normal
columnar organization of the proliferating and prehypertrophic zones
and showed a greatly expanded hypertrophic zones (Figs. 4D, E).
To better understand the growth defects mediated by over-
expression of Spry1 in Col2-Cre-expressing cells, we performed in
situ hybridization for stage-speciﬁc chondrocyte markers on serial
sections of long bones from embryos of different gestational ages. In
control embryos, aggrecan expression increased progressively from
the reserve to the proliferating zones and was undetectable in the
hypertrophic chondrocytes (Fig. 5A). In Spry1;Col2-Cre mice, aggrecan
expression was also expressed in an increasing gradient from the
reserve to proliferating zones, but remained weakly expressed in the
hypertrophic chondrocytes (Fig. 5B). The pattern of expression of Ppr
was similar between Spry1;Col2-Cre and control embryos (Figs. 5C
and D). Ihh was expressed in two distinct anatomical domains in
control mice; corresponding to upper hypertrophic chondrocytes of
long bone growth plates (Fig. 5E) and overlapping with Col10α1
expression (Fig. 5G). However, in Spry1;Col2-Cre mice, Ihh expression
was conﬁned to a single broad domain of hypertrophic chondrocytes
(Fig. 5F) which overlapped with the Col10α1 expression domain (Fig.
Fig. 4. Spry1;Col2 embryos have reduced bone formation. (A) Von Kossa staining of long bone sections at E16.5 (50×). (B) Higher magniﬁcation from rectangular area of A. Note the
persistence of hypertrophic chondrocytes and failure of formation of normal trabecular bone. (C) In situ hybridization for osteocalcin showed inhibition of osteogenesis in Spry1;Col2
growth plates. (D, E) Alcian Blue staining of E16.5 humerus sections. (D) higher magniﬁcation of D (E). Chondrocytes in CAG-GFP-Spry1 control mice formed an orderly columnar zone
(black bracket), but the same region in Spry1;Col2-Cre mice was highly disorganized. R = resting, P = proliferating, H = hypertrophic zones.
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centers of the embryonic skeleton (Inada et al., 2004). In E15.5 Spry1;
Col2-Cre embryos, Mmp13 expression was absent from hypertrophic
chondrocytes and primary ossiﬁcation centers compared to control
mice (Figs. 5I and J). However, by E16.5, Mmp13 was expressed in
hypertrophic chondrocytes of Spry1;Col2-Cre embryos, albeit in a
pattern distinct from control embryos (Figs. 5K and L). The delay and
alteration in the domains of expression of stage-speciﬁc marker gene
expression suggests a delay or premature chondrocyte differentiation.
To evaluate these possibilities, we examined Ihh and Col10α1 mRNA
expression in E13.5 limbs to test whether the onset of terminal
differentiation is also delayed (Minina et al., 2002). Robust expression
of Ihh was found in the E13.5 limbs of control CAG-GFP-Spry1
embryos (Fig. 5M); whereas in Spry1;Col2-Cre embryos, Ihh expres-
sion was slightly decreased (Fig. 5N). Interestingly, expression of Co-
l10α1, a marker of hypertrophy, was initiated at this stage in control
but not in Spry1;Col2-Cre limbs (Figs. 5O and P). Therefore, instead of
accelerating chondrocyte differentiation, overexpression of Spry1 in
nascent chondrocytes delayed chondrocyte differentiation. LacZ
staining of CAGGFP-Spry1;ROSA26;Col2-Cre triple transgenic mice at
E12.5– 13.0 reveals an overall decreased in the LacZ staining compared
to ROSA26;Col2-Cre control embryos suggesting an overall decrease in
chondrocyte proliferation and differentiation by this stage (Figs. 5Q
and R). This difference was most pronounced in the presumptive
proliferating zone.
Forced expression of mSpry1 in chondrocytes decreases proliferation and
increases apoptosis
The rate of chondrocyte proliferation and differentiation, along
with the rate of chondrocyte hypertrophy and apoptosis directs theformation of the growth plate (Ornitz and Marie, 2002). To assess the
effect of overexpression of Spry1 on chondrocyte proliferation,
pregnant CAGGFP-Spry1 mice that were crossed with Col2α1-Cre
transgenic micewere injected with BrdU at E16.5. After two hours, the
embryos were collected and BrdU incorporation into long bone
chondrocytes was detected by immunohistochemistry. The total
number of chondrocytes in the presumptive reserve and proliferating
zones of Spry1;Col2-Cre mice were markedly reduced compared to
littermate controls (data not shown). Overall, the number of BrdU-
positive cells in the epiphysis of Spry1 transgenic mice was
signiﬁcantly reduced compared to littermate controls (Figs. 6A, B).
To gain additional insight into the effects of forced expression of
mSpry1 on chondrocyte proliferation, we established primary
chondrocyte cultures from long bone growth plates. Tamoxifen-
induced expression of mSpry1 in primary chondrocytes from Spry1;
CAGGCre-ERTM mice began as early as 15 hours after the addition of
tamoxifen (Fig. 6C). This expression correlated with a decrease in the
number of tamoxifen-treated Spry1;CAGGCre-ERTM chondrocytes
relative to tamoxifen-treated controls chondrocytes (Fig. 6D). We
did not observe any evidence that this decrease in cell number was
due to increased apoptosis. These results indicate that forced
expression of mSpry1 in chondrocytes inhibited growth plate
columnar chondrocyte organization, in part by inhibiting chondrocyte
proliferation.
To determine whether there were changes in rates of apoptosis in
Spry1;Col2-Cre growth plates, we performed TUNEL labeling on
sections of E16.5 humeri of Spry1;Col2-Cre andwild-type control mice
(Fig. 7). There was increased apoptosis in the presumptive reserve and
proliferating zones of Spry1;Col2-Cre long bones but not in those of
wild-type mice. These data suggest that the disruption in the normal
columnar organization of the chondrocytes is likely due to decreased
Fig. 5. Overexpression of Spry1 in chondrocytes delayed chondrocyte differentiation and maturation resulting in accumulation of hypertrophic cartilage. (A–L) In situ hybridization
for stage-speciﬁc chondrocyte differentiation markers on sections of E16.5 humeri from CAG-GFP-Spry1 control and Spry1;Col2-Cre embryos. The reserve chondrocyte marker
aggrecan (Agc) (A, B), the prehypertrophic and hypertrophic chondrocytemarker Indian hedgehog (Ihh) (C, D), PTHrP receptor (Ppr) (E, F), hypertrophic chondrocyte marker Col10α1
(G, H, I, J), and the terminal differentiated marker MMP-13 (K, L) were employed. In situ hybridizationwas carried out on E13.5 forelimb sections from control (M, N) and Spry1;Col2-
Cre (O, P) for Ihh (M, O) and Col10α1 (N, P). LacZ staining of forelimbs (Q) and hindlimbs (R) of ROSA26;Col2-Cre (WT) and Spry1;ROSA26;Col2-Cre (Spry1) embryos.
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to the presumptive reserve and proliferating zones.
Overexpression of Spry1 in chondrocytes inhibits bone formation by
inhibiting chondrocyte terminal differentiation and removal
The delay in terminal chondrocyte differentiation could affect
hypertrophic chondrocyte elimination, which is required for forma-
tion of primary ossiﬁcation centers. Therefore, we used long-term
BrdU pulsed labeling to determine whether overexpression of Spry1
prolonged hypertrophic chondrocyte survival. Pregnant females were
injected with BrdU at E15, and 36 hours later, the embryos at E16.5
were collected and BrdU incorporation into chondrocytes was quan-
tiﬁed by immunohistochemistry. Figs. 8A and B show that the per-
centage of BrdU-positive cells in the hypertrophic zone of Spry1;
Col2-Cre growth plates was signiﬁcantly increased compared to that
of wild-type controls. Due to the growth arrest of hypertrophic
chondrocytes, the BrdU-labeled cells present in the hypertrophic
zone are cells that moved down from the proliferating zone, and will
accumulate if not removed through apoptosis. Thus, the increase in
BrdU incorporation in the hypertrophic zone of Spry1;Col2-Cre
transgenic mice reﬂects the slow elimination of these cells. To further
examine this hypothesis, we performed TUNEL labeling to determinethe rate of apoptosis of terminally differentiating hypertrophic chon-
drocytes. As expected from the BrdU results, most of the TUNEL
labeled cells were localized to the chondro-osseous junction in wild-
type but not in Spry1;Col2-Cre growth plates (Figs. 8C, D),whereas
increased apoptotic cells were observed in the chondrocytes distal to
the chondro-osseous junction of Spry1;Col2-Cre growth plates but
not in wild-type (Fig. 7). Together, these results suggest that over-
expression of Spry1 in chondrocytes delayed terminal chondrocyte
differentiation causing excessive accumulation of hypertrophic
chondrocytes, and consequently in the expansion of the hypertrophic
zone and inhibition of endochondral ossiﬁcation in Spry1;Col2-Cre
mice.
Forced expression of mSpry1 in chondrocytes sustains ERK activation
through attenuation of FGFR ubiquitinylation
The Spry family functions as feedback inhibitors of the FGFR-
activated ERK pathway at or proximal to Raf1 in many cell types
(Furthauer et al., 2002; Hanafusa et al., 2002; Iwanami et al., 2005;
Yang et al., 2006). To examine whether overexpression of mSpry1 in
chondrocytes regulates ERK signaling mediated by FGFR activation in
a similar manner, we employed immunoﬂuorescence microscopy on
E16.5 humerus sections using phospho-Mek1/2 antibodies (Fig. 9A).
Fig. 6. Overexpression of Spry1 in chondrocytes inhibited cell proliferation. (A, B) Short-term (2 h) BrdU incorporation into E16.5 mouse embryos shows the rate of chondrocyte
proliferation. Immunochemistry showed decreased BrdU-labeled cells in the region of the presumptive proliferating columnar chondrocytes (P) of Spry1;Col2-Cre mice with little
difference in the reserve chondrocytes (R) (A). Quantiﬁcation of BrdU-positive cells in Spry1;Col2-Cre sections relative to controls (B). (C, D) Tamoxifen(TM)-induced Spry1 expression
in primary chondrocytes inhibits cell growth. (C) Immunoblot analysis demonstrates tamoxifen-induced Spry1 protein expression. (D) Cell growth assay with and without
tamoxifen-induced Spry1 expression in primary chondrocytes from CAG-GFP-Spry1;CAGGCre-ERTM embryos. Assays were performed in triplicate.
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taining between reserve zone (RZ) and proliferating zone (RZ)
chondrocytes of wild-type or Spry1;Col2-Cre mice. However, thereFig. 7. Overexpression of Spry1 in chondrocytes induced premature chondrocytes
apoptosis. (A) TUNEL labeling of E16.5 humerus sections demonstrated increased
apoptotic chondrocytes in the presumptive reserve and proliferating zones of Spry1;
Col2-Cre growth plate relative to Cre-negative littermate controls. (B) Lower
magniﬁcation shows the ephiphysis. (C) Quantiﬁcation of TUNEL-positive cells as a
percentage of total chondrocytes.was an increase in phospho-MEK1/2 immunostaining in the hyper-
trophic zone (HZ) of Spry1;Col2-Cre mice. Unexpectedly, time course
analysis demonstrated that tamoxifen-induced expression of mSpry1
in primary chondrocytes from Spry1;CAGGCre-ERTM mice did not
inhibit ERK activation mediated by FGF2 stimulation, but rather
prolonged ERK activation (Fig. 9B). We noted a consistent decrease in
Spry1 protein levels in cultures stimulated with FGF2, which likely is
the result of proteasomal degradation.
The dynamic up-regulation of D-type cyclins (cyclin D1, D2, and
D3) in response to mitogenic stimulation is necessary for progression
through the G1 phase of the cell cycle (Musgrove, 2006). It was
reported that cyclin D1 antisense oligonucleotides inhibit the pro-
liferation of rat chondrosarcoma cells and primary rat chondrocytes
(Beier et al., 2001). It was of interest to determine whether sustained
ERK activation mediated by mSpry1 overexpression in chondrocytes
alters cyclin D1 expression. Similar to a previous report, the level of
cyclin D1 protein in the growth plates is undetectable by immuno-
histochemistry (Sunters et al., 1998), data not shown), whereas cyclin
D1 can be easily detected in cultures of primary chondrocytes (Li et al.,
2006). Although overexpression of mSpry1 did not alter the dynamic
pattern of cyclin D1 expression, it decreased the basal levels of cyclin
D1 (Fig. 9B). Thus, our results suggest that overexpression of mSpry1
somehow decreases cyclin D1, which may, in part, lead to a lower rate
of chondrocyte proliferation.
Although Spry proteins inhibit ERK activation mediated by several
RTKs, it was also reported that Spry2 prolonged EGFR-mediated ERK
activation by sequestering c-Cbl away from EGFR and attenuating
c-Cbl-mediated EGFR degradation (Haglund et al., 2005; Wong et al.,
2002b, 2001). This prompted us to examine the effect of Spry1 ex-
pression on the degradation pathway of FGFRs. Immunoﬂuorescence
microscopy of E16.5 growth plates with FGFR3 antibodies revealed
increased punctate staining in the presumptive reserve (Fig. 10A) and
proliferating zones (Fig. 10B) of Spry1;Col2-Cre growth plates
compared to controls. This punctate staining pattern likely represents
FGFR3 accumulation in the endosomal compartment. We also per-
formed immunoﬂuorescence microscopy for FGFR2 on primary
cultures of chondrocytes from Spry1;CAGGCre-ERTM with or without
tamoxifen-induced Spry1 expression. Fig. 10C demonstrates that
there was a more rapid accumulation FGF2-induced FGFR2
Fig. 8. Overexpressing Spry1 in chondrocytes inhibited the elimination of hypertrophic chondrocytes. (A) BrdU pulse-labeling for 36 h showed an increase of BrdU-positive cells in
hypertrophic zone (HZ). (B) Quantiﬁcation of BrdU-positive cells in A. (C) TUNEL labeling showed normal apoptotic chondrocytes in chondro-osseous junction in wild-type growth
plates but not in Spry1;Col2-Cre growth plates. (D) Quantiﬁcation of apoptotic cells in C.
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drocytes induced to express Spry1.
FGFR2, which directly or indirectly binds to c-Cbl and is degraded
through the proteasome pathway (Kaabeche et al., 2004), is abun-
dantly expressed in epiphyseal chondrocytes (Peters et al., 1993).
FGFR2 is ubiquitinated under quiescent conditions and undergoes
rapid degradation upon FGF2 stimulation (Fig.10D). Overexpression of
Spry1 in cultures of primary chondrocytes signiﬁcantly decreased
FGFR2 ubiquitination both under quiescent conditions and after FGF2
stimulation, resulting in an accumulation of FGFR2 without FGF2
stimulation (Fig. 10D).
Overexpression of mSpry1 in chondrocytes up-regulated p21Cip and
STAT1
Cell cycle inhibitors play an important role in chondrogenesis
(Ballock et al., 2000). STAT1 and p21Cipmediate increases in apoptosis
and reduced chondrocyte proliferation in constitutively active Fgfr3
mouse mutants and Fgf2 transgenic mice (Sahni et al., 2001; Su et al.,
1997). We questioned whether sustained ERK activation, as a result of
forced expression of mSpry1 in chondrocytes, signals in a manner
similar to activated FGFR3 (Sahni et al., 2001; Su et al., 1997). There-
fore, we examined p21Cip and STAT1 expression in E16.5 long bone
growth plates by immunoﬂuorescence and in situ hybridization. The
results showed that overexpression of Spry1 resulted in up-regulation
of p21Cip and STAT1 expression in hypertrophic chondrocytes, and
expanded the domain of p21Cip and STAT1 expression from the
hypertrophic zone toward the reserve zone when compared to
controls (Figs. 11A, B, and data not shown). Consistently, tamoxifen-induced expression of mSpry1 in cultures of primary chondrocytes
signiﬁcantly up-regulated p21Cip compared to control chondrocytes
(Fig. 11C). Collectively, these data indicated that forced expression of
Spry1 in chondrocytes inhibited chondrocyte proliferation, in part
through a STAT1-p21Cip pathway.
Discussion
In this study, we demonstrated that: (i) Spry1 and Spry2 were
expressed in prehypertrophic and hypertrophic chondrocytes of the
developing long bones; (ii) forced expression of mSpry1 in chon-
drocytes of embryonic mice inhibited chondrocyte proliferation with
coincident sustained ERK activation and decreased expression of
cyclin D1; (iii) forced expression of mSpry1 in chondrocytes up-
regulated the expression of p21Cip and STAT1; (iv) hypertrophic
chondrocyte apoptosis was inhibited which lead to an increase in
hypertrophic chondrocytes which inhibited endochondral bone
formation. The results suggest that Spry1 and perhaps other Spry
family members regulate FGFR signaling in a cell-type speciﬁc
manner, and that dysfunction of Spry genes in chondrocytes and
osteo-chondro-progenitor cells may play a role in some skeletal
disorders.
Spry expression in developing chondrocytes
The expression of Spry transcripts during early embryogenesis
and in adult tissues is documented (Chambers and Mason, 2000; de
Maximy et al., 1999; Minowada et al., 1999; Zhang et al., 2001).
However, the dynamic expression of Spry family members during
Fig. 9. Overexpression of Spry1 in chondrocytes results in sustained ERK activation
mediated by FGF2 stimulation. (A) Immunoﬂuorescence for phospho-MEK1/2 on E16.5
humerus sections showed no signiﬁcant inhibition of ERK signaling in the presumptive
reserve and proliferating zones of Spry1;Col2 growth plates, whereas MEK1
phosphorylation was slightly enhanced in hypertrophic zone. (B) Immunoblot analysis
of the time course of FGF2 stimulation of primary chondrocytes from Spry1;CAGGCre-
ERTM embryos showed that overexpression of Spry1 sustained ERK activation and
decreased basal cyclin D1 expression (B).
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expression in mature and hypertrophic chondrocytes during the
initial phases of endochondral ossiﬁcation. Furthermore, our in vitro
differentiation studies with ATDC5 cells and primary chondrocytes
demonstrated that Spry expression is up-regulated during early
stages of differentiation and coincides with the expression of
differentiation markers such as Ihh. These in vitro differentiation
studies support a model in which increased Spry expression may
participate in initiation or progression of the chondrocyte differ-
entiation program.
We observed extensive overlap in the expression of Spry1, Spry2,
and Spry4 in the chondrocytes of developing growth plates. Spry
family members are also co-expressed in other developmental
contexts including regions of the brain, kidney, limb bud, and
craniofacial primordia (Minowada et al., 1999; Zhang et al., 2001).
The functional signiﬁcance of this overlap has not been determined.
Recent studies may provide some insight into the biological
signiﬁcance of co-expression of Spry family members in different
tissues. Spry family members form homo- and hetero-oligomers
through their C-terminal domains (Ozaki et al., 2005). These studies
further revealed that while Spry homo-oligomers inhibited FGF-
induced activation of the ERK pathway, Spry hetero-oligomers had
greater inhibitory activity. In addition, these studies showed that
Spry1 speciﬁcally interacts with Grb2, whereas Spry4 interacts
speciﬁcally with Sos1 (Ozaki et al., 2005). The co-expression and
hetero-oligomerization of different Spry family members during
development may represent a combinatorial system for the strict
regulation of the activation state of the ERK pathway from multiple
signaling inputs. The observed increase in ERK activation in
chondrocytes overexpressing Spry1 may reﬂect a disruption in the
normal distribution of Spry oligomers.Sustained ERK activation contributes to defects in chondrogenesis
Retroviral-mediated expression of Spry2 in the prospectivewing or
limb buds of chick embryos causes a reduction of limb bud outgrowth
and an inhibition of chondrocyte differentiation, although the
mechanisms for this are not clear (Minowada et al., 1999). To examine
the role of Spry in chondrogenesis in mice, we used Cre-loxP
technology to overexpress Spry1 in chondrocytes by using Col2(α1)-
Cre to drive Spry1 expression. Interestingly, Spry1;Col2-Cre transgenic
mice develop an thanatophoric dysplasia II-like dwarﬁsm phenotype
similar to that observed in the chick limb budmodel (Minowada et al.,
1999). Longitudinal growth of long bones is achieved through the
proliferation of chondrocytes, chondrocyte hypertrophy, and endo-
chondral ossiﬁcation. BrdU incorporation showed that overexpression
of mSpry1 in chondrocytes inhibited the proliferation rate of
chondrocytes in the presumptive proliferative zone. Furthermore,
growth of primary chondrocytes in culture was inhibited by forced
expression of mSpry1. MAPK activation in response to growth factors
and cytokines is required for cell proliferation in many cell types. The
kinaseMEK1/2 is immediately upstream of ERK, and its activationmay
be used as a marker of ERK activation. The intensity of p-MEK1/2
immunostaining was similar in the reserve and proliferating zones
between control and Spry1;Col2-Cre embryos; whereas the MEK1/2
signal was increased in the hypertrophic zone in Spry1;Col2-Cre
growth plates. Interestingly, transgenic mice that express a constitu-
tively active form of MEK1 (c-MEK1) exhibit increased ERK phosphor-
ylation and achondroplasia-like dwarﬁsm (Murakami et al., 2004). In
contrast to Spry1;Col2-Cre mice, c-MEK1 transgenic mice display
incomplete chondrocyte hypertrophy, a smaller hypertrophic zone
and delayed endochondral ossiﬁcation. Furthermore, whereas chon-
drocyte proliferation was unaffected in c-MEK1 transgenic mice
(Murakami et al., 2004), chondrocytes from Spry1;Col2 had reduced
proliferative capacity. This suggests that Spry1 inhibits chondrocyte
proliferation by a mechanism that may be independent of ERK
activation.
The up-regulation of the cell cycle inhibitor p21Cip in chondro-
cytes is mediated in part by STAT1 activation, and correlates with
reduced proliferation and increased apoptosis in the resting and
proliferating zones of developing long bones (Sahni et al., 1999). FGF2
and FGF18 treatment of wild-type and Stat1-null chondrocytes results
in similar up-regulation of p21Cip, whichwas inhibited by an inhibitor
of the ERK pathway, indicating that activation of the ERK pathway by
FGFs is independent STAT1 (Murakami et al., 2004). Spry1;Col2-Cre
embryos exhibited an increase in STAT1 and p21Cip expression
relative to control embryos. However there was no increase in STAT1
phosphorylation (X.Y., unpublished). Therefore, we propose that
overexpression of Spry1 in chondrocytes inhibits their proliferation
in a manner that may be independent of ERK signaling, but is
mediated in part by up-regulation of p21Cip, in a manner that may be
independent of STAT1. The mechanism by which Spry1 expression
leads to increased p21Cip levels remains to be determined.
Spry1 regulates chondrocyte differentiation
Histological examination of long bones of E16.5 Spy1;Col2-Cre
transgenic mice showed accumulation of hypertrophic chondrocytes
that were uniformly larger than hypertrophic chondrocytes from Cre-
negative CAG-GFP-Spry1 control mice. In addition, the chondrocytes
of the proliferating and prehypertrophic zones were disorganized in
Spry1;Col2-Cre growth plates when compared to Cre-negative
littermate controls. Expression of Ihh and Col10α1, two markers of
chondrocyte differentiation, were decreased in the limbs of Spry1;
Col2-Cre transgenic as early as E13.5. However, by E15.5 the intensity
of Ihh and Col10α1 expression was similar between Spry1;Col2-Cre
embryos and Cre-negative littermates; but the domains of expression
were different. In Cre-negative control mice, Col10α1 was expressed
Fig. 10. Overexpression of Spry1 resulted in accumulation of FGFRs in chondrocytes possibly through inhibiting degradation of FGFRs. Immunoﬂuorescence microscopy showed an
increase of FGFR3 immunoreactivity in the reserve zone (A) and proliferating zone (B) in Spry1;Col2-Cre growth plates. (C) Primary chondrocytes from Spry1;CAGGCre-ERTM embryos
were induced to express Spry1 by the addition of 1 μM tamoxifen for 48 h, followed by the addition of FGF2 for the indicated times. Immunoﬂuorescence staining for FGFR2 demonstrated
a more rapid accumulation of FGFR2 in nucleus when Spry1 was overexpressed. (D) Primary chondrocytes from Spry1;CAGGCre-ERTM embryos (DP) or Cre-negative controls (SP) were
treatedwith 1 μM tamoxifen (TM) for 48 h. Chondrocytes were then either left unstimulated (Q) or stimulatedwith FGF2 for 15 min. Immunoprecipitationwith FGFR2 antibodies showed
FGF2 stimulation induced degradation of FGFR2, and overexpression of Spry1 inhibited ubiquitination of FGFR2 in the quiescent state, and resulted in accumulation of FGFR2.
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primary ossiﬁcation center inwhich there was no Col10α1 expression.
In contrast, Col10α1 expression was restricted to a single broad zone
of expression with no intervening primary ossiﬁcation center. The
expression domains for Agc and Ppr were similar between Spry1;
Col2-Cre and control E15.5 embryos. This suggests that expression
of Spry1 in chondrocytes delays or inhibits the terminal stages chon-
drocytes differentiation and maturation.
Overexpression of mSpry1 in chondrocytes inhibits FGFR degradation
and leads to sustained ERK activation
Attenuation of growth factor signaling is essential for the re-
gulation of developmental processes and tissue homeostasis in most
organisms. Spry family members were originally identiﬁed as
feedback inhibitors of FGFR-ERK signaling in many cell types and in
embryonic organogenesis (Mason et al., 2006). FGFR constitutively
associates with the adaptor protein FRS2 through the juxtamem-
brane domain, and after stimulation by FGF ligands, become
phosphorylated on six tyrosine residues that serve as docking sites
for the SH2 domain-containing proteins, Grb2 and SHP2. This results
in the recruitment and assembly of Grb2-Sos complexes at the
membrane, where Ras is activated (Hanafusa et al., 2002). In
addition, upon FGF stimulation, Spry1 and Spry2 are translocated
to the plasma membrane where they become tyrosine phosphory-
lated on a conserved N-terminal tyrosine residue that acts as a
docking site for Grb2, thus sequestering Grb2 away from Sos and
resulting in attenuation of Ras activation (Hanafusa et al., 2002).Conversely, upon ligand stimulation of the EGFR that is internalized
in complex with the SH2 domain-containing E3 ubiquitin ligase c-
Cbl, Spry2 becomes tyrosine phosphorylated on the conserved N-
terminal tyrosine residue (Y55) that serves as a docking site for c-Cbl.
Tyrosine phosphorylated Spry2 then binds c-Cbl and sequesters it
away from the EGFR, resulting in sustained EGFR and consequently
sustained ERK activation (Haglund et al., 2005; Stang et al., 2004).
Like EGFR, FGFR is also internalized upon ligand stimulation,
although the mechanisms may be different. Ligand-stimulated
activation of FGFR results in phosphorylation of FRS2 and c-Cbl,
leading to formation of a c-Cbl–Grb2 complex that is recruited to
FRS2. The recruitment of the c-Cbl–Grb2 complex by FRS2α results in
the ubiquitinylation and degradation of FRS2α and FGFR (Wong et al.,
2002a). FGF stimulation has also been reported to enhance Spry2
degradation via the proteasome (Hall et al., 2003).
Here we demonstrate that forced expression of Spry1 in chondro-
cytes causes decreased ubiquitinylation of FGFR2 that result in in-
creased FGFR2 levels under both quiescent and FGF-stimulated
conditions. FGFR3 levels were also increased in chondrocytes over-
expressing Spry1. These data suggest that the increase in sustained ERK
activation that we observe in Spry1 overexpressing chondrocytes may
be due to Spry1-mediated attenuation of FGFR degradation, resulting in
increased signaling to ERK. This mechanism probably involves Spry1-
mediated sequestration of c-Cbl because the Spry-Cbl binding site is
highly conserved among Spry family members. Spry1 likely sequesters
c-Cbl away from FGFR-FRS2-Grb2 complexes thus preventing their
ubiquitination and proteasome-mediated degradation. Because Spry
binding to Cbl can occur without tyrosine phosphorylation of Spry
Fig. 11. Overexpression of Spry1 up-regulates STAT1 and p21Cip in vivo and p21Cip in vitro. E16.5 humerus sections from Spry1;Col2-Cre embryos or their Cre-negative littermates
were stained with STAT1 antibody (A) and p21Cip antibody (B). Sections were also stained with DAPI to visualize nuclei, and the two images were merged. (C) Primary chondrocytes
from Spry1;CAGGCre-ERTM embryos were induced to differentiate by the addition of ascorbic acid (ASA), for 3 days, followed by the addition of 1 μM tamoxifen (TM). Cells were
harvested on days 4, 5, and 6 and subjected to immunoblot analysis. Control and Spry1-expressing chondrocytes treated with ascorbic acid show increased p21Cip expression in the
presence of induced Spry1 expression.
75X. Yang et al. / Developmental Biology 321 (2008) 64–76(Fong et al., 2003;Wong et al., 2001), perhaps Spry1 preferentially binds
to c-Cbl in chondrocytes, thereby (i) resulting Spry degradation, (ii)
leaving Grb2 available to be recruited to FGFR-FRS2, (iii) resulting in
decreased FGFR-FRS2 degradation and sustained ERK activation. Our
data support this possibility. Future studies on the role of Spry in various
cellular contexts will likely focus on the availability and afﬁnity of Spry
and its different binding partners.
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